The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
Good point meldrew I recall one of the presentations mentioning other applications but with the focus on delivering a working machine for cancer treatment didn't give it the recognition it probably deserves.
The main concern at present is whatever finance is arranged doesn't wipe out small PI's. I realise it will affect all shareholders including directors & institutions but they may be looked after within any arrangement although I'm expecting that to be the case and we all get a fair and reasonable outcome.
I know max it's been a rough journey you could decribe as a complete mess but one way or another they keep finding the funds. Now possibly just a few months away from patient treatment and visible evidence of a fully assembled and working machine the sp looks as if the complete opposite is true and that news of total failure is due.
This AIM market leaves much to be desired if it does fail then the market is reading it correctly but if they succeed you've got to question what's going on here in what could potentially destroy such a worthwhile technical achievement. Not much we can do other than wait for the announcement which one way or another will either cement the poor opinion of the BoD many have or restore their reputation and allow this project to progress to completion. Hopefully won't be going down with the Titanic and news will arrive soon. I'm not buying anymore and will continue to hold to what is looking like to the very end!
Not entirely true particularly in the biotech sector although the current sp is supporting your theory.
The potential benefit of Light especially Flash technology to this sector is huge. To be able to treat a wide range of cancers in a single Flash treatment will be an incredible achievement.
If you look at the values of biotech companies in early phase cancer drug development showing some promise they are significantly higher than avo yet years away from commercialisation. The development of these drugs is massively complex and takes years and years with regulatory approval just as long winded. The drugs are also often targeted to very specific cancer types so will not be of use to many other unfortunate cancer sufferers.
Having a machine like Avo's Light to compliment these treatments and be able to zap tumours with reduced side effects from collateral radiation damage will be a great advancement in the overall effort to improve the treatment of cancer.
The additional financing is going to incur some short term damage to the sp but once they get through this hurdle to the other side the future could and should be very promising. There will be not be a single cure for cancer but many improving complimentary treatments that allow for longer term survival and better quality of life for cancer sufferers. Light is one such treatment that needs to succeed so the sooner the funding is dealt with the better so that they can push on with patient treatment and regulatory approval. The market will then sort itself out and be substantial, shame it's not as forwards looking as with drug development but this is new groundbreaking stuff that the market doesn't appear to value correctly at present.
Well said u89 I didn't realise how the patients practically had zero hope/chance of benefitting from this trial with most not even having a type of disease that would normally be treated with dox. Some lunatics on the other BB were claiming that this would be headline news on the BBC with miracle cures announced if it was going well and as expected just trying to scaremonger. Now you see the detail of what's involved in the trials you understand AS's carefully chosen words to explain progress and how long the process is.
Even for the soon to begin next phase as mentioned in the presentation patients will have to chose between being given a known to help course of dox or AVA6000 which may or may not work better. The good thing for the patients who chose AVA6000 is that at least without DLT's they still could be given straight dox if for whatever reason their type of disease did not respond well to AVA6000. Let's hope for a good outcome for all involved and the resulting improving sp will be pleasing for all the right reasons.
Well having watched a bit more of the presentation in particular Andrew Saunders and Dr Tam I'd be amazed if we don't see substantial progress in the US. The size of some of the trials Dr Tam discussed involving over 600 patients worldwide could be where AVA6000 is heading and no doubt nasdaq funding or involvement with a major company being a distinct possibility.
One simplified view from the SD is that this is no cure for cancer which is not going away. There are a multitude of cancer types and many types of treatments that will coexist for years to come. Some of the claims I've read of other treatments superior efficacy and advanced development in no way reflects the complexity of the problem. These treatments are highly specific and targeted to a unique set of circumstances.
Dox is one such treatment and has been around for 50yrs so is well understood and works very effectively for the types of cancer it is used to treat. Unfortunately due to toxicity it is limited to the length of time it can be used and the types of patient it can be administered to therefore only extends patients lives for up to around 24 months as the cancer returns.
You can see a scenario of not only significantly more patients being able to be treated with AVA6000 but also it's continued use as an ongoing treatment for the life of each patient to keep the cancer under control.
This will massively increase the market for dox which I understand is around $1.5B.
Dr Tam came across as really motivated to progress the development of soft tissue sarcoma STS treatment with dox in a modified improved form such as AVA6000 even suggesting such a treatment could become the 'standard of care' overnight!
He didn't just come to the SD to present some slides, he's taking this to the US to run with the next phase of the trial at a much greater and significant level. There is still a long way to go and much work to be carried out but if phase 2 progresses in this way with the significance of who is involved and potential size of the trials the value of AVA6000 will be set inline with other similar deals that we all know about courtesy of information already provided by well informed posters.
Good luck max, against my better judgement I too finally bought some more yesterday, not quite got down to your average but it's getting lower. Hopefully we all make something out of this after so long or at the very least get our money back.
The previous 25p placings with all the outstanding warrants was valuing avo at around 200m which seemed reasonable. They can't issue shares below 25p so the current situation is concerning and creates much uncertainty around future funding. The current sp in no way reflects the progress made based on the recent operational update unless something has changed that we are not aware of but you'd think the last director purchases were intended to alleviate any concerns. As things stand with what is known once funds are secured you would expect it to be at a value reflecting the true worth and not based on a beaten down sp due to the aim scaremongering brigade. I'm sure they're trying to nail this down asap and we'll get an update when it's concluded.
Driving I agree and with your predicted valuation of 2 to 300m. I've been holding for years and your recent purchases have resulted in you exceeding my total with a far lower average so congrats to you and anyone else buying at what seems like bargain basement prices. Hopefully you, I and all other holders will be rewarded when this current difficult financing situation is resolved.
I'm not sure the 8.3p equation for the last raise is correct as they have to purchase each warrant for 25p so 1 share plus 2 warrants would cost 75p.
Good luck to everyone buying at this ridiculously low sp wish I could justify releasing some cash to join in makes my 22p last purchase annoying to say the least could have had 3x more shares.
After the amazing news of 230MeV can't believe the sp is this low still think the assets and IP are worth in excess of £200m. If all is progressing as per the last update it can only be as a result of the aim vultures preying on the huge uncertainty of raising finance. No doubt it will be dilutive but if raised and progress towards accreditation continues should patient treatment be successful the potential sp gains from here you'd think would be significant.
I think if the boss of apple comes out with a very similar sounding statement below we can have a bit of sympathy for cpx and AK. Hopefully being much smaller and more nimble CPX's fortunes will turn round sooner as they navigate through this difficult period. The company hasn't become bad because of what is going on around it.
The update came as many firms warn about a sharp economic slowdown, especially in the tech sector which boomed during the pandemic.
Apple boss Tim Cook said the firm was navigating a "challenging environment".
He blamed the sales decline on supply shortages due to Covid-19 disruption in China - where its phones are manufactured - and a strong dollar, as well as wider economic weakness stemming from rising prices, the war in Ukraine and lingering effects from the pandemic.
Yep 56m but I think it's telling how in their last update they mention 200m raised in addition to loans taken out and looking to slash costs by 30%.
Sets up for a takeover with an initial payment at least what has been invested and further payments on achieving full accreditation to a level that will satisfy existing major shareholders. 60p now and a further 60p following accreditation or thereabouts.
Still an absolute giveaway but if a major player with all the manufacturing and global sales/support infrastructure gets hold of this at least it has a chance of commercial success that it really deserves. A much better outcome than what some negative people seem to wish upon this company.
I wouldn't say that PR it's fair to say the cpx sales team are crap infact totally **** is probably a better description and the accuracy of comms leaves a lot to be desired.
But their technology especially prizmatic is world leading and the IP has resulted in securing other products. So inspite of themselves at some point with the wide scale adoption of supercapacitors success will land on their doorstep. I would suggest as part of their cost cutting process to get rid of a few sales directors.
Good luck BB I feel torn at this price but won't be adding. I have a lot invested here at a large loss that will be corrected with the values I have in mind. Whilst a large purchase at this level would boost my profits if it turns out that way, it could still all go tits up so I will now sit and wait having bought my last lot at around 22p but I really can't see that machine ending up in the scrap heap. A competitor to Siemens/Varian would be desperate to get hold of this technology and it wouldn't be for less the 300m
Good luck with all your efforts don't want to put anyone off but I have a substantial holding but won't be joining.
I'm of the MIKECC opinion complete waste of time what the BoD say but one day because of the technology cpx will land on its feet with a juggernaut sized deal that they probably didn't even see coming. Sales wise they are a very dubious outfit how long can you get away with boasting 60m pipeline and achieve derisory sales figures is not good. It's all basic sales stuff you wouldn't survive in most companies if that's how you qualify opportunities.
Don't want to be too negative as I've said not impressed with the so called sales people at cpx (taking murata orders is not selling btw) but the technology stands out and the market is moving in the right direction not withstanding the current turmoil and when the two collide by accident the shareholders will get their rewards.
Meant sense as well what an effort this has been. Anyway hopefully this turns around soon. How they go about securing these funds is going to be a real eye opener. A 50m mcap company raising 75m to 85m.
The reality is the sp should be at around 60p mcap 300m with 50m raised no problem and 25m loan and fighting off bids as 500m to 1b mcap is where it should be.
The only reason this hasn't been snapped up I believe is because the major shareholders have been loyal holders for many years at a much higher price and won't agree to a giveaway sale. If financially all falls into place I'll take that as a massive vote of confidence even with the expected dilution.
For some reason doesn't like the phrase directors talk interviews as all one word
***************************
Just replace the asterisk with above
https://www.***************************/advanced-oncotherapy-expected-to-disrupt-the-market-says-hardman-co-lonavo/4121102571
Accepting the fact hardman are slightly biased in their opinion this article makes a lot of sence to the potential value of avo & also mentions the option of a takeover that a few here feel is the way forwards.
Totally agree MCC & JT91 very relevant opinions. Most of my disappointment and frustration stems from this year being the transformational year after holding for many years. As annoying as it is will just have to reset timescales for what may well be a 24month turnaround. That said things can change very quickly and it will be out of the blue but a significant deal could land at any moment. Justifiable finger pointing at the BoD but in hindsight is it really surprising with all the known global issues at present. Whilst the BoD appeared blind to it from early comms let's hope they are equally as blind to any big deals coming there way so they can drop that bombshell news on us as well....I wish!